Manufacturing of Bulk Drugs
Contents

India Pharmaceuticals Sector
Uttarakhand – India`s Emerging Pharma hub
Uttarakhand Pharma cluster
Project Concept
Market Potential
Growth Drivers
Uttarakhand Competitive advantage
Project Outline
Project Financials
Infrastructure Availability
Project Structure
Policies, Schemes & Incentives
Key Contacts

*Draft project report only for reference.
India - Pharmaceuticals Sector

**INDIAN PHARMA SECTOR - OVERVIEW**

- India is leading player in global generics market with a 20% share in supplies by volume and strong network of 10,500+ manufacturing units and 3,000 pharma companies.

- Indian pharmaceutical market increased by 7.4% from 2016 and is valued at USD 19.15 billion in FY17 and is expected to reach USD 28.94 billion by 2022 experiencing a CAGR of 8.6%.

- It supplies 50 to 60% of global demand for many vaccines (including ARVs)*

- India supplies 60% of global ARV drugs and 30% of the annual UNICEF requirement.

- Government of India allows 100% Foreign direct Investment (FDI) in Greenfield pharma and 74% in Brownfield pharma under automatic route.

- Indian vaccines are exported to 150 countries and more than 500 different Active Pharmaceutical Ingredients (APIs) are manufactured in India. The pharmaceutical export value was USD 14.1 Billion in 2017, and is forecast to rise to USD 20.54 Billion by 2022.

- Indian pharmaceutical companies account for 30% of the US's generic drug imports with exports to the US and other regulated western markets accounting for over 50% of the country's global medicine exports.

- India has the largest number (over 200) of US Food and Drug Administration (FDA)-approved pharmaceutical units outside the US.

- India has the second highest number of US FDA approved facilities and labour costs in Indian have been lower than other manufacturing hubs by up to 40%.

*Source: FICCI report on 2018 India pharma sector, IBEF - 2018 Pharmaceuticals report, POBOS- McKinsey’s proprietary pharma operations benchmarking
India – Pharmaceuticals Sector

INDIAN PHARMA SECTOR - EMERGING OPPORTUNITIES

Active Pharmaceuticals Ingredients (API)
- India became the third largest global generic API merchant market in 2016, with a 7.2 per cent market share
- The Indian pharmaceutical industry accounts for the 2nd largest number of Abbreviated New Drug Applications (ANDAs), is the world’s leader in Drug Master Files (DMFs) applications with the US

Contract research & Mfg. Services
- Fragmented market with more than 1,000 players
- CRAMS industry is estimated to reach USD 18 billion in 2018 and expected to witness a strong growth at a CAGR of 18-20 per cent between 2013-18

Pharmaceutical Industry

Formulations
- Largest exporter of formulations in terms of volume, with 14% market share and 12th in terms of export value. Drug formulation exports from India reached USD 7.25 billion during April - November 2017
- Domestic market size currently valued at US$ 11.2 billion

Bio-similar
- The government plans to allocate USD 70 million for local players to develop Bio-similar.
- The domestic market is expected to reach USD 40 billion by 2030

INDIAN PHARMA SECTOR - GROWTH FORECASTS

Pharmaceutical Market Forecast

Uttarakhand - India`s emerging Pharma Hub

**UTTARAKHAND STATE OVERVIEW**

- There are more than 300 pharmaceutical units engaged in manufacturing in Uttarakhand, majorly located in Selaqui, Haridwar and Udham Singh Nagar.
- Currently Pharmaceutical sector employs more than 1,00,000+ people in Uttarakhand.
- Currently, the Pharmaceuticals Industry of Uttarakhand is catering to around 20% of country’s domestic requirement & Uttarakhand state is on a track of becoming global Pharma hub.
- With Uttarakhand State`s focus on pharmaceutical and infrastructure investments, pharma majors have made their base in Uttarakhand.
- In order to facilitate Pharmaceutical industries in the State, well-developed infrastructure has been established at Pharma City Selaqui Industrial Area, Dehradun. Spread across 50 acres, with a capital investment of INR 12059.62 Lakhs. It is providing employment to more than 1200 people.
- Abundant skilled manpower is available in the State. The Uttarakhand Skill Development Mission trains students for employment under Pharmaceutical Sector with special courses and industry collaborations.

**KEY INVESTMENT OPPORTUNITIES**

- API/Bulk Drug Manufacturing Unit
- Food & drug testing and Contract research Lab
- Biosimilars manufacturing Unit
- Vaccines manufacturing Unit
- Nutraceuticals Manufacturing Unit
- Lifesciences reagent manufacturing Unit focused on research Labs
# Uttarakhand - Pharma Cluster

### PHARMA CITY, SELAQUI INDUSTRIAL AREA, DEHRADUN

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Particular</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Name of Industrial Estate</td>
<td>Pharma City, Selaqui Industrial Area, Dehradun</td>
</tr>
<tr>
<td>2</td>
<td>Location</td>
<td>Located 25 Km from Dehradun. 225 Km from National Capital Delhi.</td>
</tr>
<tr>
<td>3</td>
<td>Total Area</td>
<td>50 Acres</td>
</tr>
<tr>
<td>4</td>
<td>Area Available for Allotment (Industrial)</td>
<td>30 Acres</td>
</tr>
<tr>
<td>5</td>
<td>Area Allotted</td>
<td>30 Acres</td>
</tr>
</tbody>
</table>
| 6       | Connectivity                            | Nearest Rail Yard: 25 Km  
Nearest National Highway: Located on Dehradun-Chakrata National Highway  
Nearest Domestic Airport: Jolly Grant 55 Km  
Nearest International Airport: Delhi 275 Km |
Project Concept (1/2)

Manufacturing of Bulk Drugs Overview

The drug manufacturing industry entails manufacture, extraction, processing, purification and packaging of chemical material to be used as medications.

It can be primarily classified in to two stages

- Primary processing: Production of Active Pharmaceutical ingredient (API) or bulk drug
- Secondary processing: Conversion of the API in to products suitable for administration

Bulk drug/API is the biologically active ingredient in a pharmaceutical drug. It is used in a finished pharmaceutical product (FPP), intended to be used for pharmacological activity.

The US (38%), Japan (11%), China (10%), Germany (9%) and France (8%) were the top five markets of bulk drug in 2014.

Types of Bulk Drugs

<table>
<thead>
<tr>
<th>Structure</th>
<th>Production</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biologics</td>
<td>Extracted from semi-synthesized or biological sources</td>
</tr>
<tr>
<td>Small molecules</td>
<td>Chemically synthesized</td>
</tr>
<tr>
<td></td>
<td>Sophisticated production process</td>
</tr>
<tr>
<td></td>
<td>Mass produced</td>
</tr>
</tbody>
</table>

Market Overview

Currently, the global industry is dominated by synthetic chemical APIs. However, biopharmaceutical APIs are gradually gaining importance due to the growth of the biotechnology industry.

100% (USD b)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>122</td>
<td>129</td>
<td>137</td>
<td>147</td>
<td>159.5</td>
<td>175</td>
</tr>
</tbody>
</table>

Source: 1. Technavio report on Global active pharmaceutical ingredients market, 2015-2019
## Facilities at the Proposed API Manufacturing Plant

<table>
<thead>
<tr>
<th>Facility</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Technical Facility</td>
<td>The facility will be in alignment with international guidelines such as the WHO good manufacturing practices (GMP) standards.</td>
</tr>
<tr>
<td></td>
<td>Technical Plant will be equipped with SS and Glass Lined reactors having capacity 160 Lit. to 5000 Lit. S Sand MS Rubber Lined Centrifuges, Tray dryer, Filters etc.</td>
</tr>
<tr>
<td>Pharma Facility</td>
<td>The department will have 5 litre. Glass assemblies to carry out production of API in small batch sizes. Besides this, the section would be equipped with 3 separate modules where 3 separate products could be processed at the same time maintaining all GMP and FDA norms.</td>
</tr>
<tr>
<td></td>
<td>The Pharma area will have equipment for handling finished products such as Tray Dryer, Air Jet Mill, Sifter, Blender, Multi Mill and packing area. Pharma area will also have separate facilities to store materials of different stages.</td>
</tr>
<tr>
<td>Quality Control Facility</td>
<td>The proposed facility would have a Quality Control department which can perform visual, dimensional, mechanical and analytical tests.</td>
</tr>
<tr>
<td>Supply Chain Management (SCM) Facility</td>
<td>Key instruments would include TOC Analyzer, Gas Liquid Chromatograph, Total Organic Carbon analyzer, Ultra Pure Water purification system, Video Microscope, Fourier Transform Infra Red Spectrophotometer, Automatic Glass Ware Washing and Drying Machine, High Performance Liquid Chromatographs.</td>
</tr>
<tr>
<td></td>
<td>SCM activities will include: production planning, inventory control, warehousing and Bonded storeroom management and information technology to generate EIS and MIS reports for analysis.</td>
</tr>
<tr>
<td>Engineering Services Facility</td>
<td>The department works as support function for the entire plant activity, including new project, API production, administration, estate up keep, environmental Controls and ensures compliance of all statutory as well as regulatory directives</td>
</tr>
<tr>
<td>Raw Material Storage</td>
<td>RM Stores will have 100% controlled environment storage and inactive raw materials Dispensing of raw materials will be carried out as per prevailing GMP norms and SOPs.</td>
</tr>
</tbody>
</table>
Market Potential

Global Trends

- The Global Active Pharmaceutical Ingredients (API) Market is poised to grow at a CAGR of around 6.6% over the next decade to reach approximately USD 238.8 billion by 2025.
- Rising cost pressures, increasing production, outsourcing and growing demand for generics are currently driving growth in the industry, globally

India Trends

Indian bulk drugs industry constituted 8% of the global API industry in 2017. However, the growth of this industry is expected to outpace the global growth due to increasing exports and Government’s increasing focus on the sector.

India:
- Is one of the largest provider of generic medicines globally
- Has second-highest US-FDA approved plants, after the US
- Is expected to be among the top-3 pharmaceutical markets in terms of incremental growth by 2020 and sixth largest market globally in absolute size

- India is the third-largest global generic API merchant market, with a 7.2% market share
- The Indian pharmaceutical industry, which accounts for the second-largest number of Abbreviated New Drug Applications (ANDAs), is the world’s leader in Drug Master Files (DMFs) applications with the US. Indian companies filed for 52% of the total DMF filings in 3Q15

Source: Technavio report on Global active pharmaceutical ingredients market, 2015-2019
Source: Share of India API in Global manufacturing- ASSOCHAM

Indian bulk drugs market (USD b)

Source: Technavio report on Global active pharmaceutical ingredients market, 2015-2019

Indian bulk drug market segmentation by production process

Source: Share of India API in Global manufacturing- ASSOCHAM

100% (USD 10.2b)
- World API
- India API
Growth Drivers (1/2)

Growth in the bulk drug sector is expected to be driven by exports and Government’s increasing focus on the sector

Cost-effective manufacturing: Indian bulk drugs manufacturers have a distinct advantage in terms of their low manufacturing costs and advanced chemistry skills. Low direct input costs (labor and raw material) gives Indian bulk drug companies an added advantage over their peers operating in regulated markets such as the US. Cost of production in India is 65% lower than in the US and 50% of that in Europe.

Large number of USFDA-approved manufacturing plants: India only lags behind the US in terms of the number of USFDA-approved manufacturing plants in the country. Its high-class manufacturing capabilities enable it to provide high-quality products to international markets.

Product differentiation: Indian bulk drugs manufacturers are facing intense competition from other emerging markets. As a result, several Indian manufacturers are shifting focus on both low-cost production and product differentiation. Several manufacturers offer value-added services, such as the production and procurement of intermediates.

Increasing concentration on particular therapies: Many Indian bulk drug manufacturers are targeting niche therapy areas with limited competition (such as dermatology and CNS).

Demand for generics in India has increased with the Government setting up Jan-Aushidhi Stores to promote generics and improve access of rural population to healthcare facilities.

More than 30% of the APIs manufactured in India are exported to countries such as US, UK, Japan, etc. The total production market of API in India was valued at approximately USD 11 Billion in FY 2016. This market is forecasted to grow at a CAGR of around 9% during the period of FY 2016-FY 2022.

Favourable policies like relaxed FDI norms and GST will help grow API manufacturing industry in the Country.

Source: Indian API Industry and Imports: Research and Information System for developing countries, Indian API Market Outlook, ASSOCHAM
Government Initiatives

► Government of India is planning a new bulk drug policy (based on the following recommendations of Katoch committee) with an aim to produce 100% of bulk drugs domestically. The incentives include:

► Setting up of three large API manufacturing clusters/mega parks across states; to be equipped with facilities such as common effluent treatment plants, testing facilities, assured power supply, IPR management

► Multiple financial incentives (such as 15-year tax holiday for cluster developers/participants), land and other infrastructural facilities at concessional rates, interest subsidies on bank loans (through interest subvention up to 7.5%), and import duty exemption on capital goods in respect of API manufacturing

► Income tax benefits for an initial period of 10 years for each product from date of launch of product

► Single-window environmental clearance to API manufacturers for all drugs once the plant is approved by the environment ministry

► Proposal to set up adventure capital fund with corpus of around INR 500 crore to aid pharma SMEs

► 100% FDI in Pharmaceuticals Sector Manufacturers are also free to produce majority of drugs duly approved by the Drug Control Authority, without the need of an additional industrial license

Source: Katoch Committee report on active pharmaceutical ingredients (APIs) - 2017
Uttarakhand- Competitive Advantage

Pharma Manufacturing Clusters

300 pharma units in Uttarakhand
1,00,000 people employed
20% of India`s production

Favourable places to manufacture APIs

Other Advantages

- Pharmaceutical industry needs continuous power, Uttarakhand ensures uninterrupted Power supply to the industry

- Ecosystem
  20% of the Nation`s pharmaceuticals products are produced in the state. All gamut of Pharmaceuticals are manufactured in Uttarakhand with ample availability of raw material.

- Strategic location and excellent infrastructure
  - State has well connectivity with national capital and 2 inland container depots to facilitate export in the state.
Project Information

Estimated Manpower Requirement

<table>
<thead>
<tr>
<th>R&amp;D</th>
<th>Operations</th>
<th>Management</th>
<th>Ancillary Support</th>
<th>Workers</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>25</td>
</tr>
</tbody>
</table>

Potential Collaboration Opportunities

- The API manufacturing unit can collaborate with veteran education institutes (like NIPER Ahmedabad, Maharaja Sayajirao University of Baroda) for R&D as well as for providing practical training to the students.
- The manufacturing unit could also collaborate with leading foreign players to leverage the technology.

Major players: API manufacturing

India’s bulk drugs industry is highly fragmented. In 2013, out of 10,000 India-listed pharma manufacturers in India, nearly 70% were involved in drug formulation and 30% were API producers.

Leading API manufacturers in India*:

- MacLeod’s Pharmaceutical Limited
- Glenmark Pharmaceuticals Ltd.
- Aurobindo Pharmaceuticals
- Dr. Reddy’s Laboratories
- Ranbaxy Laboratories Limited
- Dishman Pharmaceuticals
- Lupin
- Cipla Limited
- Matrix Laboratories
- Orchid Chemicals & Pharmaceuticals
- Divi’s Laboratories
- Sun Pharmaceuticals
- Ipca Laboratories
- Cadila Healthcare
- Alembic Limited

* Source: FICCI
# Project Financials

## Estimated Project Cost

<table>
<thead>
<tr>
<th>Project components &amp; specifications</th>
<th>Cost (INR Crores)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site development (site levelling, internal roads, sewage lines, water supply, drainage, landscaping, street lighting) (Area: 3,055 sq meter, Average rate: INR 1,200 per square meter)</td>
<td>0.4</td>
</tr>
<tr>
<td>Building and construction (Built-up area: 2,350 square meter, Average rate: INR 25,000 per square meter)</td>
<td>5.9</td>
</tr>
<tr>
<td>Machinery and equipment</td>
<td>7.7</td>
</tr>
<tr>
<td>Miscellaneous fixed assets (Furniture and fixtures)</td>
<td>0.01</td>
</tr>
<tr>
<td>Environmental protection measures</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>Sub-total</strong></td>
<td><strong>14.0</strong></td>
</tr>
<tr>
<td>Contingency (@10%)</td>
<td>1.4</td>
</tr>
<tr>
<td><strong>Sub-total</strong></td>
<td><strong>15.4</strong></td>
</tr>
</tbody>
</table>

### Assumptions
- **Benchmarks:** based on proposed plant for API manufacturing
- **Inflation:** between 2017-2018 has been accounted for the calculations.

Note: Above project cost is an indicative project cost and may vary based on the scale and requirements at the time of setting up the facility.
Ease of Doing Business

Under the ‘Ease of Doing Business’ initiative, the State has implemented a web based Single Window Clearance System - [www.investuttarakhand.com](http://www.investuttarakhand.com), allowing investors to avail the necessary State Government approvals to establish and start their business operations through a single platform without any physical touch point with the approving / licensing authority.

- **150 +** Regulatory Reforms Undertaken
- **100 +** Timelines notified under Uttarakhand Enterprises Single Window Facilitation & Clearance Act 2012
- **50+** New Standard Operating Procedures drafted for Departmental services
- **40+** New Online Systems Developed

### Hassle Free Setup and Operations in the State

<table>
<thead>
<tr>
<th>Online Single Window System for all required approvals</th>
<th><strong>Auto Renewal</strong> of Consent to Establish, Consent to Operate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single Point <strong>Sectoral Clearances</strong></td>
<td><strong>Self / Third party certification</strong> in lieu of departmental inspections</td>
</tr>
<tr>
<td>Investment facilitation centre to handhold investors</td>
<td><strong>Single Integrated Return</strong> for all labour laws</td>
</tr>
<tr>
<td>Objective Criteria for land allotment</td>
<td>Use of modern <strong>SCADA</strong> System to ensure <strong>reliable</strong> supply of electricity</td>
</tr>
<tr>
<td>Geographic Information System of all land banks</td>
<td><strong>Commercial Court</strong> set up in Dehradun with entire state jurisdiction</td>
</tr>
</tbody>
</table>
INVESTOR FACILITATION

► The Government of Uttarakhand has laid huge emphasis on business facilitation by creating an enabling environment for industries to set up and start their operations in the State.

► The State government houses a dedicated ‘Investment Promotion & Facilitation Centre (IPFC)’ which acts as a centralized one-stop-shop for the investors / businesses and provides complete handholding support in a structured, focused and comprehensive manner. IFC will focus on investment promotion, facilitation, direct engagement and consultation with investors / Stakeholders and ensures investment realization and sustainable industrialization in the state.

► ‘Uttarakhand Right to Service Act, 2011’ & ‘The Uttarakhand Enterprises Single Window Facilitation and Clearance Act, 2012’ were enacted to provide necessary time bound licenses, permissions and approvals for the setting up of commercial establishments in the state. The State has ensured robust legal resolution mechanisms to ensure time bound delivery of government services with more than 100 investor related services already notified under both the acts separately and is in the process of adding more such services of multiple sectors shortly.

CREDITED BY INDUSTRY ASSOCIATIONS

Story of `Make in Uttarakhand` which started in 2003 is a classic example of what manufacturing can deliver to a region`s economy in terms of both economic growth and employment generation

-CII Report `Making Uttarakhand Competitive, June 2016`

NCAER Assessment based on “Perception of good business climate” ranks Uttarakhand as the Least Corrupt state in India

NCAER N-SIPI Index Survey ; Five states – Uttarakhand, Gujarat, Assam, Andhra Pradesh and Himachal Pradesh - had more than 90% respondents say they faced no problem in getting land

Uttarakhand has emerged as the top state in the country in terms of growth in the industry and service sectors in the last ten years. Uttarakhand has also figured as the second best performing state in terms of project implementation, improving investment scenario in the state.
### Indicative Project Structure & Approvals (1/2)

**INDICATIVE PROJECT STRUCTURE**

Incumbent investor will fund, build, operate and maintain the facility. Uttarakhand State will help in getting land, obtaining approvals on single window system.

**INDICATIVE LIST OF CLEARANCES**

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Name of Service</th>
<th>Authority/ Agency/ Office/ Department officer granting approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Land allotment in departmental industrial estates</td>
<td>Directorate of Industries</td>
</tr>
<tr>
<td>2</td>
<td>Application for new connection LT / HT line – non domestic / industrial</td>
<td>Uttarakhand Power Corporation Limited</td>
</tr>
<tr>
<td>3</td>
<td>Application for Water Connection</td>
<td>State Infrastructure and Industrial Development Corporation of Uttarakhand Limited</td>
</tr>
<tr>
<td>4</td>
<td>Application for Water Connection</td>
<td>Uttarakhand Jal Sansthan</td>
</tr>
<tr>
<td>5</td>
<td>Application for building plan approval</td>
<td>State Industrial Development Authority</td>
</tr>
<tr>
<td>6</td>
<td>Application for Completion cum Occupancy Certificate</td>
<td>State Industrial Development Authority</td>
</tr>
<tr>
<td>7</td>
<td>Consent to Establish under Water (Prevention and Control of Pollution) Act, 1974</td>
<td>Uttarakhand Environment Protection and Pollution Control Board</td>
</tr>
<tr>
<td>8</td>
<td>Consent to Establish under Air (Prevention and Control of Pollution) Act, 1981</td>
<td>Uttarakhand Environment Protection and Pollution Control Board</td>
</tr>
</tbody>
</table>
### Indicative List of Clearances

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Name of Service</th>
<th>Authority/ Agency/ Office/ Department officer granting approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Application for Pre-Establishment Fire NOC (National Building Code, 2005)</td>
<td>Uttarakhand Fire and Emergency Services</td>
</tr>
<tr>
<td>11</td>
<td>Application for Pre-Operational Fire NOC (National Building Code, 2005)</td>
<td>Uttarakhand Fire and Emergency Services</td>
</tr>
<tr>
<td>12</td>
<td>Site Plan Approval under Factories Act, 1948</td>
<td>Department of Labour</td>
</tr>
<tr>
<td>13</td>
<td>Registration of Factories under Factories Act, 1948</td>
<td>Department of Labour</td>
</tr>
<tr>
<td>14</td>
<td>Registration under Uttarakhand Dookan Aur Vanijya Adhishthan Adhiniyam, 1962</td>
<td>Department of Labour</td>
</tr>
<tr>
<td>15</td>
<td>License under Contract Labour Act, (Regulation and Abolition),1970</td>
<td>Department of Labour</td>
</tr>
<tr>
<td>16</td>
<td>Registration under GST (Uttarakhand Goods and Services Tax Rules, 2017)</td>
<td>Department of Commercial Tax</td>
</tr>
</tbody>
</table>
Policies, Schemes & Incentives (1/2)

Mega Industrial and Investment Policy 2015

Industrial development Scheme 2017

Financial Incentives available

- Interest Subsidy
- Capital Subsidy
- Stamp Duty Subsidy
## Mega Industrial and Investment Policy 2015

### Amendment (2018) - Highlights

#### Coverage:
New & Existing Projects undergoing expansion (falling within identified Industrial Estates: Large projects (50 Cr to 75 Cr), Mega Projects (75 Cr to 200 Cr), Ultra Mega Projects (Above 200 Cr)

<table>
<thead>
<tr>
<th>Interest Subsidy</th>
<th>SGST Concession*</th>
<th>Stamp Duty</th>
</tr>
</thead>
<tbody>
<tr>
<td>7% for 5 years</td>
<td>Large: 30%</td>
<td>50% Exemption</td>
</tr>
<tr>
<td>Investment - Interest</td>
<td>Mega / Ultra Mega: 50%</td>
<td></td>
</tr>
<tr>
<td>Large - 25L Max</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mega - 35L Max</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ultra Mega - 50L Max</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The SGST after adjustment of ITC on sale of finished product (B2C) will be reimbursed from the date of commencement of production of the unit

<table>
<thead>
<tr>
<th>ETP Subsidy</th>
<th>Extra Employment Subsidy</th>
<th>Land Registration Fees</th>
<th>Power Assistance</th>
<th>Land Rates Rebate</th>
</tr>
</thead>
<tbody>
<tr>
<td>30% (up to 50 lacs)</td>
<td>@ 500 P.M. per Male</td>
<td>Land registration fee @1/- per 1000/-</td>
<td>Rebate of 1/- per unit on the power bill and 100% rebate on electric duty for 7 years</td>
<td>Rebate of 15%, 25% and 30% on SIIDCUL prevailing land rate for Large, Mega and Ultra Mega Projects respectively</td>
</tr>
<tr>
<td></td>
<td>@700 P.M. per Female</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Industrial Development Scheme 2017

- **Central Capital Investment**
  - Central Capital Investment Incentive for access to credit (CCIIAC)
  - @ 30% of the investment in plant and machinery with an upper limit of INR 5.00 crore

- **Central Comprehensive Insurance Incentive**
  - Reimbursement of 100% insurance premium on insurance of building and Plant & Machinery for a maximum period of 5 years from the date of commencement of commercial production/operation

**Note:** Units which have commenced production on or after 01st of April, 2017 will be allowed to register with DIPP on or before 30th of September, 18
# Key Contacts

## Investment Facilitation Centre

<table>
<thead>
<tr>
<th>Address</th>
<th>Directorate of Industries</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Industrial Area, Patel Nagar, Dehradun, Uttarakhand</td>
</tr>
<tr>
<td>Website</td>
<td><a href="http://www.investuttarakhand.com">www.investuttarakhand.com</a></td>
</tr>
<tr>
<td>Email ID</td>
<td><a href="mailto:ifc.uttarakhand@gmail.com">ifc.uttarakhand@gmail.com</a></td>
</tr>
<tr>
<td>Toll Free</td>
<td>18002701213</td>
</tr>
</tbody>
</table>

## Uttarakhand Medical Health and Family Welfare

<table>
<thead>
<tr>
<th>Address</th>
<th>Health Directorate, Dandalokhand P.O. Gujrara, Sahastradhara Road, Dehradun, Uttarakhand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Website</td>
<td><a href="https://www.ukhfws.org">https://www.ukhfws.org</a></td>
</tr>
<tr>
<td>Email ID</td>
<td><a href="mailto:drugcontroluk@gmail.com">drugcontroluk@gmail.com</a></td>
</tr>
<tr>
<td>Phone</td>
<td>0135-2608646</td>
</tr>
</tbody>
</table>

**Disclaimer:** This project profile is based on preliminary study to facilitate prospective entrepreneurs to assess a prima facie scope. It is, however, advisable to get a detailed feasibility study prepared before taking a final investment decision.